Lipid compositions with the ability to self-assemble into biocompatible nano-and mesostructured functional materials have many potential uses in modern medicine. By using twocomponent lipid systems, it is possible to tune the structure formation and related functional properties, e.g., the encapsulation and extended release of small molecules and peptides, by simply varying the ratio of the lipid building blocks. This is shown in detail for the binary phosphatidylcholine and diglyceride lipid systems, which are currently being used in multiple programs for the development of novel pharmaceuticals and marketed products.
The ability of certain lipids to self-assemble into functional reversed-phase nonlamellar liquid crystal (LC) gels in contact with aqueous media, make such systems highly interesting for use as ambient responsive delivery systems using such functional features as bioadhesion, biodegradation, encapsulation, and controlled release. 1 By exploiting the liquid-to-LC gel transition triggered on exposure of lipid solutions to aqueous media, it is possible to combine excellent in vivo encapsulation and extended release properties of some reversed LC gel phases, with the easy manufacturing and administration properties of relatively low-viscosity nonaqueous lipid solutions comprising small amounts of nonaqueous solvent. 1, 2 The most frequently used nonlamellar LC-forming lipid in drug delivery-related studies has been glycerol monooleate (GMO). 3, 4 At physiological conditions in excess water, GMO forms a bilayer-based bicontinuous cubic phase (V 2 ) with the Pn3m space group representing a three-dimensional network of hydrophilic and hydrophobic domains. Although a promising candidate for several applications, GMO-based LCs have been shown to exhibit a pronounced tendency to disrupt membrane structures, e.g., extensive hemolytic activity. 5 Furthermore, the one-component GMO system has further limitations with respect to the drug delivery application in the difficulty of compensating for any phase changes caused by solubilizing drug compounds. 6 The use of a two or multicomponent system can typically alleviate this issue and can allow for compensation of unwanted phase changes by simply adjusting the ratio of the lipid building blocks. One example of such a system is the two-component unsaturated (e.g., dioleoyl) phosphatidylcholine (PC) and glycerol dioleate (GDO) system, where PC has a preference for the planar lamellar LC phase (L ¡ ) and GDO for the reversed liquid micellar phase (L 2 ). Between these extremes at full hydration reversed 2D hexagonal (H 2 ), reversed micellar cubic (I 2 ) with the Fd3m space group as well as two-and three-phase regions are formed.
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A recent study on the in vitro release of disodium fluorescein from soy PC (SPC)/GDO nonlamellar LCs has shown that the minimum of release (lowest release rates) can be found for compositions in the two-phase region between the H 2 and I 2 phases.
1 Importantly, the observed release of both for small molecules 1 and peptides 2 from these phases are significantly more restricted compared with, e.g., corresponding release rates from the highly viscous GMO V 2 phase; this shows the importance of phase morphology and the usefulness of H 2 and I 2 phases of the SPC/GDO system in long-acting delivery applications. Indeed, the pharmacokinetic (PK) profile obtained after the injection (rat) of SPC/GDO-based formulation comprising somatostatin 114 shows a stable and dose-proportional plasma concentration of this peptide for over one week, despite a circulation half-life of only a few minutes. 1, 12 Another example illustrating the unique long-acting in vivo release properties of SPC/GDO formulations was recently provided for the peptide leuprolide acetate. 2 When benchmarked against leading commercial injection depot products based on poly-(lactic-co-glycolactic) (PLGA) polymers, the SPC/GDO system was found to provide both a lower initial release (low "burst" release) and more consistent plasma leuprolide levels over time. 2 Here, we have studied in detail the equilibrium aqueousphase behavior and phase structures for the two-component SPC and GDO system as a function of lipid composition by using synchrotron small-angle X-ray scattering (SAXS) at the I711 and I911-4 beamlines at MAX-lab (Lund University, Sweden). Details of sample preparation and SAXS experiments are described in Supporting Information (SI). 13 Figure 1a presents the measured SAXS profiles of fully hydrated mixtures of SPC/GDO between lipid ratios of 70:30 and 20:80 by weight at every 2.5 wt %. Figure 1b shows the SAXS data of fully hydrated SPC/GDO mixtures in a more narrow composition region between 42:58 and 35:65 at every 1 wt %.
As seen from SAXS data in Figures 1a and 1b , the phase behavior of SPC/GDO is indeed more rich and complex than the reported phase sequence for DOPC/GDO system in excess water conditions. At a low GDO content and up to SPC/GDO weight ratio of 62.5:37.5, a 2D H 2 phase is formed that is characterized by five distinctive reflections at relative positions in ratios of 1:
ffiffi ffi 3 p :2: ffiffi ffi 7 p :3. 14 The calculated lattice parameter (a) for 2D H 2 phase decreases from 7.66 to 7.25 nm between SPC/ GDO ratio of 70:30 and 62.5:37.5. With increasing GDO content, a cubic phase starts to emerge, which is a one-phase region that exists between SPC/GDO ratios of 50:50 and 45:55. This is clearly shown by the location of the relative positions in ratios of the first 9 Bragg peaks, i. (Figure 2a) . With increasing GDO content, the obtained a value for this phase varies from 18.7 to about 17.3 nm, related to the increasing negative curvature and/or decreasing swelling ability of the cubic phase. At even higher GDO concentration, an extremely narrow region of another LC phase is located between SPC/GDO weight ratios of approximately 42:58 and almost 40:60 (Figure 2b) . 20 Bragg peaks were identified, and their positions and indexing are summarized in SI. 13 Indexing of SAXS data of this phase was achieved by assuming 3D hexagonal close packing (hcp) structure. The following relation was used where the d hkl is related to the two lattice parameters, a and c, and where R = c/a:
The analysis clearly shows that the structure of this phase is consistent with the hcp lattice of identical spherical reversed micelles having the P6 3 /mmc symmetry. The calculated lattice parameters for this 3D hexagonal phase are a = 6.99 and c = 11.35 nm with a c/a ratio of 1.624, which is very close to the value for the ideal hcp lattice of identical spheres, R ideal = ffiffi ffi 8 p :3 = 1.633. In addition, the intensities of obtained SAXS reflections are similar to those obtained for the 3D hexagonal P6 3 /mmc phase of other lipid 15 and surfactant 16 systems in water.
Between SPC/GDO weight ratios of approximately 39:61 and 37:63, a very narrow region of yet another LC phase was identified. SAXS data of this phase is shown in Figure 2c . It shows at least 30 Bragg reflections that are not consistent with cubic or 3D hexagonal lattices of neighboring phases, and we were unable to resolve its structure. We can only speculate that since it is between the P6 3 /mmc and Fd3m phases, its structure should be "intermediate" between hexagonally close-packed identical micelles and the cubic Fd3m lattice consisting of two types of reversed micelles.
Starting from the SPC/GDO ratio of 35:65, the cubic Fd3m phase that shows a very nice SAXS pattern with at least 15 Bragg peaks is found again (Figure 2d ). With increasing GDO content, the calculated a value for this phase decreases from about 15.81 to 15.42 nm before transforming into a reversed micellar phase (L 2 ) at a SPC/GDO weight ratio of 20:80.
The intricate phase behavior of fully hydrated SPC/GDO mixtures described here has not been observed before. Most of the studies were performed with mixtures of dioleoylphosphatidylcholine (DOPC)/GDO, which shows a less rich phase behavior. 810 Our results (see SI) confirm that DOPC/GDO mixtures only form the H 2 and Fd3m phases in excess-water conditions. The existence of the P6 3 /mmc phase was not demonstrated for the pure DOPC/GDO (at a weight ratio of 40:60) system at limiting hydration. 17 The formation of 3D hexagonal phase was only shown for the ternary DOPC/GDO/ cholesterol system. 14 Here, it should also be noted that contrary to our findings, the previously determined phase behavior of fully hydrated SPC/GDO also shows no formation of the P6 3 / mmc and "intermediate" unknown phases. 11 The reason for this difference is that the authors in that study used D 2 with the formation of only the H 2 and Fd3m phases in the lipid mixture composition region.
In conclusion, fully hydrated SPC/GDO mixtures with increasing GDO content forms the following phase sequence:
Note that the reappearance of the Fd3m phase at a different GDO content is not surprising and does not contradict the Gibbs phase rule. These two phases are indeed interconnected at limited hydration values (see SI), and they form a onephase region. Our findings show that the two-component diacyl lipid system is rich in phase behavior, and as shown in previous studies, 1,2 the system presents a high potential for encapsulation and long-acting release of small molecules and peptides, which are emphasized by the current portfolio of drug development programs in early-to-late clinical stages.
